Mobile

ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosi...

Update Il y a 4 ans
Reference: EUCTR2009-011169-98

ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to compare the change in 6-minute walk distance (6MWD) after initiating ambrisentan or placebo treatment in subjects with pulmonary hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF).

Inclusion criteria

  • Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis

Links